News & Updates
Filter by Specialty:
Add-on evolocumab improves plaque characteristics in statin-treated CAD patients
In individuals with stable coronary artery disease (CAD), intensifying their lipid-lowering regimen with evolocumab, a PCSK9* inhibitor, led to improvements in coronary plaque characteristics on intravascular imaging, findings from the YELLOW III trial have shown.
Add-on evolocumab improves plaque characteristics in statin-treated CAD patients
15 Mar 2023
NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC
In a post hoc analysis of two prospective studies, netupitant/palonosetron (NEPA) combined with dexamethasone has demonstrated similar efficacy vs a quadruplet regimen of olanzapine, aprepitant, ondansetron, and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in Chinese women with early breast cancer (BC) receiving doxorubicin/cyclophosphamide (AC) in Hong Kong.
NEPA- and olanzapine-based regimens similarly effective at preventing CINV in early BC
15 Mar 2023
Looking on the bright side helps with poststroke recovery
When it comes to functional recovery after stroke, the adage “always look on the bright side” appears to be true, with a recent study providing evidence that optimism is associated with better recovery.
Looking on the bright side helps with poststroke recovery
14 Mar 2023
Which factors predict progression from discoid lupus to severe SLE?
A diagnosis of discoid lupus erythematosus (DLE) at age 25 years or below, phototype V to VI, and antinuclear antibody titers of ≥1:320 are significantly associated with the development of severe systemic lupus erythematosus (SLE), according to a study.
Which factors predict progression from discoid lupus to severe SLE?
14 Mar 2023
Women at a disadvantage in care, outcomes for acute chest pain: study
Mortality for ST-segment elevation myocardial infarction (STEMI) is higher for women, but they tend to have better outcomes for other aetiologies of chest pain compared with men, a study has shown.
Women at a disadvantage in care, outcomes for acute chest pain: study
14 Mar 2023
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.